[go: up one dir, main page]

WO2009001364A3 - Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers - Google Patents

Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers Download PDF

Info

Publication number
WO2009001364A3
WO2009001364A3 PCT/IL2008/000884 IL2008000884W WO2009001364A3 WO 2009001364 A3 WO2009001364 A3 WO 2009001364A3 IL 2008000884 W IL2008000884 W IL 2008000884W WO 2009001364 A3 WO2009001364 A3 WO 2009001364A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
polymer
active agents
containing polymers
residues
Prior art date
Application number
PCT/IL2008/000884
Other languages
French (fr)
Other versions
WO2009001364A2 (en
Inventor
Jallal M. Gnaim
Muhammad Athamna
Original Assignee
Capsutech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsutech Ltd filed Critical Capsutech Ltd
Priority to EP08763640A priority Critical patent/EP2170054A4/en
Priority to CA002692021A priority patent/CA2692021A1/en
Priority to US12/666,939 priority patent/US20100226987A1/en
Publication of WO2009001364A2 publication Critical patent/WO2009001364A2/en
Priority to IL202849A priority patent/IL202849A0/en
Publication of WO2009001364A3 publication Critical patent/WO2009001364A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A targeting conjugate is provided comprising an active agent, one or more residues of a cyclodextrin (CD)-containing polymer and a biorecognition molecule. The polymer is preferably a peptide or a polypeptide comprising at least one amino acid residue containing a functional side group to which at least one of the CD residues is linked covalently; the biorecognition molecule is covalently bonded directly or via a spacer to the polymer backbone of the CD-containing polymer; and the active agent is noncovalently encapsulated within the cavity of the cyclodextrin residues and/or entrapped within the polymer matrix of the CD-containing polymer.
PCT/IL2008/000884 2007-06-28 2008-06-29 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers WO2009001364A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08763640A EP2170054A4 (en) 2007-06-28 2008-06-29 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CA002692021A CA2692021A1 (en) 2007-06-28 2008-06-29 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
US12/666,939 US20100226987A1 (en) 2007-06-28 2008-06-29 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
IL202849A IL202849A0 (en) 2007-06-28 2009-12-20 Targeting conjugates comprising active agent encapsulated in cyclodextrin-containing polymers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94677507P 2007-06-28 2007-06-28
US60/946,775 2007-06-28

Publications (2)

Publication Number Publication Date
WO2009001364A2 WO2009001364A2 (en) 2008-12-31
WO2009001364A3 true WO2009001364A3 (en) 2010-02-18

Family

ID=40186125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000884 WO2009001364A2 (en) 2007-06-28 2008-06-29 Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers

Country Status (4)

Country Link
US (1) US20100226987A1 (en)
EP (1) EP2170054A4 (en)
CA (1) CA2692021A1 (en)
WO (1) WO2009001364A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
CN101935365B (en) * 2010-08-25 2012-03-21 华东理工大学 Method for synthesizing brain targeting head modification cyclodextrin (CD) derivative
US20120213854A1 (en) * 2010-09-30 2012-08-23 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
CN103747798B (en) * 2011-05-18 2018-10-26 马特里瓦克斯公司 Include the protein matrix vaccines composition of polycation
EP2809686A4 (en) * 2012-01-31 2015-11-25 Cerulean Pharma Inc Cyclodextrin-based polymers for therapeutic delivery
US9480704B2 (en) 2012-03-21 2016-11-01 Cosmederm Bioscience, Inc. Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
ES2930524T3 (en) * 2012-03-21 2022-12-14 Galleon Labs Llc Topically administered strontium-containing complexes for the treatment of pain, itching and inflammation
AU2013274450A1 (en) * 2012-06-12 2015-01-15 Cornell University Nanosystems for formulation of effective minimum risk biocides
ES2984397T3 (en) 2012-06-19 2024-10-29 Ambrx Inc Anti-CD70 antibody drug conjugates
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US10064954B2 (en) * 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
MX394528B (en) 2016-11-08 2025-03-24 Regeneron Pharma STEROIDS AND PROTEIN CONJUGATES THEREOF.
KR20250008984A (en) * 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 Cyclodextrin protein drug conjugates
IL274427B2 (en) 2017-11-07 2024-11-01 Regeneron Pharma Hydrophilic linkers for drug-antibody conjugates
CN118955604A (en) 2018-01-08 2024-11-15 里珍纳龙药品有限公司 Steroid compounds and antibody conjugates thereof
US11377502B2 (en) 2018-05-09 2022-07-05 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
CN114470237B (en) * 2022-03-21 2023-12-19 中国科学院长春应用化学研究所 A virus-like structural gene vector, drug delivery system, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210527A1 (en) * 2005-02-16 2006-09-21 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
FR2705350B1 (en) * 1993-05-13 1995-07-07 Oreal New derivatives of mono (6-amino 6-deoxy) cyclodextrin substituted in position 6 by an alpha-amino acid residue, their preparation process and their uses.
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
DE10018617A1 (en) * 2000-01-13 2001-10-31 Joerg G Moser Cyclodextrin dimers with peptide spacer structures for detoxification of active pharmaceutical ingredients with high potential for side effects
BR0315198A (en) * 2002-10-09 2005-08-30 Insert Therapeutics Inc Cyclodextrin-based materials and compositions and uses thereof
CA2633801A1 (en) * 2005-12-19 2007-06-28 Capsutech Ltd. Cyclodextrin-containing polymers and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US20060210527A1 (en) * 2005-02-16 2006-09-21 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery

Also Published As

Publication number Publication date
CA2692021A1 (en) 2008-12-31
EP2170054A2 (en) 2010-04-07
US20100226987A1 (en) 2010-09-09
WO2009001364A2 (en) 2008-12-31
EP2170054A4 (en) 2012-08-08

Similar Documents

Publication Publication Date Title
WO2009001364A3 (en) Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
Lai et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy
Chang et al. Smart linkers in polymer–drug conjugates for tumor-targeted delivery
Zagorodko et al. Polypeptide‐Based Conjugates as Therapeutics: Opportunities and Challenges
Veronese et al. PEG− doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity
MX373429B (en) Factor viii polymer conjugates
EP2626080A3 (en) Conjugated factor VIII molecules
WO2008053362A3 (en) Bioresponsive polymers
Sonker et al. Review of recent advances and their improvement in the effectiveness of hydrogel-based targeted drug delivery: A hope for treating cancer
WO2007062610A3 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
WO2007069068A3 (en) Cell penetrating peptide conjugates for delivering nucleic acids into cells
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2006108052A3 (en) Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
EP3704262A1 (en) Multiplexed analysis of materials for tissue delivery
WO2008069824A3 (en) Compositions and methods for transport of molecules with enhanced release properties across biological barriers
WO2008129106A3 (en) Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof
WO2005082023A3 (en) Heterocyclic self-immolative linkers and conjugates
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
WO2011112482A3 (en) Polymeric drug delivery conjugates and methods of making and using thereof
WO2008089403A3 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
JP2014058562A5 (en)
NZ593311A (en) Albumin binding peptide-mediated disease targeting
WO2009070380A3 (en) Water-soluble carbon nanotube compositions for drug delivery and medical applications
WO2008013735A3 (en) Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763640

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2692021

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008763640

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12666939

Country of ref document: US